Cassava Sciences (NASDAQ:FLNA) Stock Price Up 1.9% – Should You Buy?

Posted by Brian Himes on Sep 23rd, 2026

Cassava Sciences, Inc. (NASDAQ:FLNA – Get Free Report)’s stock price traded up 1.9% during trading on Monday . The stock traded as high as $0.7670 and last traded at $0.7395. Approximately 336,456 shares traded hands during trading, an increase of 39% from the average daily volume of 242,665 shares. The stock had previously closed at $0.7260.

Analysts Set New Price Targets

A number of equities research analysts recently commented on FLNA shares. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Cassava Sciences in a report on Tuesday, May 26th. Wall Street Zen lowered shares of Cassava Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cassava Sciences in a research note on Monday, July 20th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cassava Sciences currently has an average rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Stock Report on FLNA

Cassava Sciences Stock Performance

The firm has a market cap of $42.03 million, a PE ratio of -1.00 and a beta of -0.69. The stock has a 50 day simple moving average of $0.90 and a two-hundred day simple moving average of $1.32.

Cassava Sciences (NASDAQ:FLNA – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported ($0.18) EPS for the quarter.

Hedge Funds Weigh In On Cassava Sciences

An institutional investor recently raised its position in Cassava Sciences stock. Caitong International Asset Management Co. Ltd increased its position in shares of Cassava Sciences, Inc. (NASDAQ:FLNA – Free Report) by 465.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,606 shares of the company’s stock after buying an additional 11,200 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Cassava Sciences were worth $27,000 as of its most recent filing with the SEC. Institutional investors own 38.05% of the company’s stock.

Cassava Sciences Company Profile

(Get Free Report)

Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology.

Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use.